Article | May 19, 2022

Global Pharma Chooses Eastern Europe For Clinical Research

Source: OCT Clinical
global market growth

The U.S. Food and Drug Administration (FDA) published its Novel Drug Approvals Report for 2021. 33 out of 50 drugs underwent clinical trials in Eastern Europe. With the total population pool of 300 million, countries like Poland, Latvia, Hungary, Romania, Czech Republic, Ukraine, Bulgaria, Russia, Georgia, Belarus and Kazakhstan demonstrate record-breaking recruitment rates with a significant number of treatment naïve study subjects.

Read the annual Industry Pages report, prepared by OCT Clinical, a European CRO, to find out why global pharma considers the region as the best destination for their clinical research activities.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader